Emergent buys Protein Sciences in $75M deal

Emergent BioSolutions has inked a deal to buy 25-year-old Protein Sciences for $75 million or more. Protein Sciences has been developing a new flu vaccine, FluBlok, relying on a new method that grows a virus in cells from caterpillars--one of a number of new cellular programs that are aiming at replacing the egg-based approach employed now. Emergent sells an anthrax vaccine and is looking to build a manufacturing facility for the flu vaccine.

"Meriden (Connecticut) is under active consideration for expanded manufacturing as we work to build on the infrastructure that is now in place," Tracey Schmitt, an Emergent spokeswoman, told the Hartford Courant. "We expect to launch FluBlok and to expand production capacity from the Meriden site and to retain all of the approximately 50 employees currently at that location."

- check out Emergent's release
- read the report in the Hartford Courant
-
read the story in the Washington Post

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.